Bortezomib-Induced Complete Heart Block and Myocardial Scar: The Potential Role of Cardiac Biomarkers in Monitoring Cardiotoxicity

Table 1

Multiple myeloma treatment summary with relevant clinical and laboratory parameters.

	5/23/2013; Prechemotherapy	6/18/2013; VCD, 1 cycle	8/6/2013; VCD, 3 cycles; Change to RVD	10/1/2013; RVD, 2 cycles	12/3/2013; RVD, 4 cycles	12/30/2013; RVD, 5 cycles
IgA (mg/dL)	1758	2358	2130	1377	885	492
M Spike (g/dL)	2.91	2.7	2.0	2.0	1.2	0.7
BUN (mg/dL)	16	22	25	19	11	11
Creatinine (mg/dL)	0.95	1.0	1.2	0.9	0.9	0.9
24-hour urine protein (g)	19.8		2.4		0.78	1.0
Blood pressure (mmHg)	127/72	119/58	108/63	120/66	107/67	117/69
Pulse (bpm)	80	60	75	63	71	69